Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Wilson Therapeutics in connection with directed share issue
Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

 Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024